Kimberly-Clark
KMB
$97.49
-0.47%
Kimberly-Clark Corp. is a leading global manufacturer in the consumer defensive sector, primarily focused on personal care and consumer tissue products through iconic brands like Huggies, Kleenex, and Cottonelle. The company operates as a dominant market leader in the essential household and personal products industry, with a significant presence in North America and a growing footprint in international markets. The current investor narrative is heavily focused on the company's planned acquisition of Kenvue's consumer health portfolio in the second half of 2026, which represents a major strategic expansion, alongside ongoing debates about its ability to navigate a challenging revenue environment and maintain its attractive dividend yield amidst a significant stock price decline.…
KMB
Kimberly-Clark
$97.49
Related headlines
Investment Opinion: Should I buy KMB Today?
Rating: Hold. The core thesis is that Kimberly-Clark is a financially leveraged company in a fundamental downturn, but its deeply depressed valuation and high yield provide a margin of safety for patient, income-oriented investors, making it unsuitable for growth portfolios but a potential hold for yield-seekers willing to accept the turnaround risk.
Supporting this view are four key data points: 1) The forward P/E of 12.9x is a meaningful discount to the trailing multiple and implies a significant earnings recovery is already priced in. 2) Revenue contraction of -17.2% YoY is severe and shows no clear sign of abating. 3) The dividend yield of 4.94% is supported by strong TTM FCF of $2.38B, offering compensation for the wait. 4) The stock trades just 5.6% above its 52-week low, suggesting most bad news may be priced in, but also reflecting a lack of positive catalysts.
The two biggest risks are the persistent revenue decline and the high financial leverage. This Hold rating would upgrade to a Buy if quarterly revenue growth turns positive or stabilizes, or if the forward P/E compresses further below 11x on sustained FCF. It would downgrade to a Sell if revenue decline accelerates beyond -20% YoY, or if the debt-to-equity ratio rises above 5.5x ahead of the Kenvue deal. Relative to its own history and the defensive staples sector, the stock appears fairly valued to slightly undervalued based on forward earnings, but the valuation is not compelling enough to offset the clear operational headwinds.
Sign up to view all
KMB 12-Month Price Forecast
Kimberly-Clark is a classic 'show me' story trapped between a compelling yield and deteriorating fundamentals. The AI assessment is neutral because the severe price decline has likely captured much of the near-term operational risk, but there is no visible catalyst for a re-rating higher. The high dividend yield acts as a put option, limiting downside for income investors, while the leveraged balance sheet and shrinking revenue cap the upside. The stance would upgrade to bullish on evidence of revenue stabilization (e.g., two consecutive quarters of sequential growth) or a successful, non-dilutive financing plan for the Kenvue acquisition. It would turn bearish if quarterly FCF shows signs of deterioration threatening the dividend.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kimberly-Clark's 12-month outlook, with a consensus price target around $126.74 and implied upside of +30.0% versus the current price.
Average Target
$126.74
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$78 - $127
Analyst target range
Analyst coverage for Kimberly-Clark is limited, with only 6 analysts providing estimates, indicating this large-cap stock may have subdued institutional interest relative to its size. The consensus sentiment appears mixed to neutral, with recent institutional ratings including actions like 'Hold' from Deutsche Bank, 'Overweight' from Piper Sandler, 'Neutral' from UBS, and a 'Sell' from Citigroup. The average target price is not explicitly provided in the data, so implied upside cannot be calculated. The estimated EPS range for the forward period is $8.98 (low) to $10.03 (high), and the estimated revenue range is $35.57 billion (low) to $38.74 billion (high), indicating a degree of uncertainty around the company's recovery trajectory. The high end of the EPS target assumes successful execution on margins and the integration of the Kenvue assets, while the low end likely factors in continued revenue pressure and integration risks. The pattern of recent ratings shows stability, with most firms reaffirming existing Hold or Neutral stances, signaling a wait-and-see approach among analysts pending clearer signs of a fundamental turnaround or progress on the acquisition.
Bulls vs Bears: KMB Investment Factors
The evidence currently favors the bear case due to the severity and persistence of fundamental deterioration, specifically the 17.2% YoY revenue decline and high financial leverage of 4.77x. However, the bull case is supported by a compelling valuation disconnect, with a forward P/E of 12.9x pricing in a deep earnings recovery, and strong free cash flow underpinning a 4.9% yield. The single most important tension in the investment debate is whether the company's severe revenue contraction is a temporary, cyclical issue or a sign of permanent market share loss and brand erosion. The resolution of this tension, likely visible in upcoming quarterly sales figures, will determine if the current valuation represents a deep value trap or a genuine turnaround opportunity.
Bullish
- Deeply Undervalued Forward P/E: The stock trades at a forward P/E of 12.9x based on analyst EPS estimates of $9.14, which is a significant discount to its trailing P/E of 16.6x. This implies the market is pricing in a substantial earnings recovery, creating a potential value opportunity if the company executes.
- Strong Free Cash Flow Supports Dividend: Kimberly-Clark generates robust TTM free cash flow of $2.38 billion, providing ample coverage for its dividend, which yields 4.94%. The payout ratio of 82% is high but sustainable given the company's defensive cash flows.
- Oversold Technical Condition: The stock price of $97.60 is down 32.15% over the past year and trades just 5.6% above its 52-week low of $92.42. This severe decline, coupled with a low beta of 0.31, suggests the stock is deeply oversold and may have limited near-term downside.
- Strategic Acquisition Potential: The planned acquisition of Kenvue's consumer health portfolio in H2 2026 represents a major strategic expansion into adjacent categories. If executed well, it could diversify revenue and drive long-term growth.
Bearish
- Severe Revenue Contraction: Q4 2025 revenue of $4.08 billion declined 17.21% year-over-year, continuing a multi-quarter downtrend from $4.13 billion in Q3. This indicates fundamental challenges with volume, pricing, or market share.
- High Financial Leverage: The company's debt-to-equity ratio of 4.77 is extremely high, indicating significant financial risk. This elevated leverage could constrain financial flexibility, especially ahead of the large Kenvue acquisition.
- Profitability and Margin Pressure: Operating income fell from $621 million in Q3 2025 to $507 million in Q4 2025, signaling margin compression. The net margin of 12.23% in Q4 also shows pressure from rising costs or lower sales.
- Chronic Underperformance vs. Market: The stock's 1-year relative strength versus the S&P 500 is -60.36%, indicating severe and sustained institutional selling or loss of investor confidence that may not reverse quickly.
KMB Technical Analysis
The prevailing price trend for Kimberly-Clark is a pronounced and sustained downtrend, with the stock posting a 1-year price change of -32.15%. The current price of $97.60 sits near the lower end of its 52-week range, trading at approximately 19% above its 52-week low of $92.42 and 32% below its 52-week high of $144.23. This positioning suggests the stock is deeply oversold and may represent a value opportunity, though it also reflects significant fundamental and sentiment headwinds that have driven the price down. Recent short-term momentum shows a slight divergence, with a 1-month price change of +1.56%, indicating a potential stabilization or minor bounce from deeply depressed levels, though this is overshadowed by the severe 3-month decline of -12.42%. This divergence could signal a temporary relief rally or mean reversion within a broader bearish trend, especially as the stock's 1-month relative strength versus the S&P 500 is a stark -4.75%. Key technical support is clearly defined at the 52-week low of $92.42, while resistance lies at the recent high near $111.44 from late February. A decisive breakdown below $92.42 would signal a continuation of the downtrend, whereas a sustained move above the $110-$111 level could indicate a more meaningful recovery is underway. The stock's beta of 0.31 indicates it is significantly less volatile than the broader market, which is typical for a defensive consumer staples name but has not shielded it from severe underperformance, as evidenced by its -60.36% 1-year relative strength versus the S&P 500.
Beta
0.31
0.31x market volatility
Max Drawdown
-35.3%
Largest decline past year
52-Week Range
$92-$141
Price range past year
Annual Return
-31.2%
Cumulative gain past year
| Period | KMB Return | S&P 500 |
|---|---|---|
| 1m | -0.2% | +5.4% |
| 3m | -6.9% | +10.9% |
| 6m | -7.1% | +11.0% |
| 1y | -31.2% | +28.1% |
| ytd | -3.9% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KMB Fundamental Analysis
Kimberly-Clark's revenue trajectory is currently under pressure, with the most recent quarterly revenue of $4.08 billion for Q4 2025 representing a year-over-year decline of -17.21%. This follows a sequential decline from $4.13 billion in Q3 2025, indicating a multi-quarter trend of contracting sales. The revenue segment data shows the Consumer Tissue segment contributed $1.52 billion in a recent period, but without a full segment breakdown, the overall trend points to broad-based challenges, likely driven by volume pressures, pricing normalization, and foreign exchange headwinds. The company remains profitable, with Q4 2025 net income of $499 million and a gross margin of 35.91%. However, profitability metrics show pressure; the net margin for the quarter was 12.23%, and the trailing twelve-month net margin stands at 11.74%. Comparing sequential quarters, Q4 2025 operating income of $507 million was down from $621 million in Q3 2025, suggesting margin compression, though gross margins have remained relatively stable in the 35-36% range. The balance sheet and cash flow position presents a mixed picture. The company carries a high debt-to-equity ratio of 4.77, indicating significant financial leverage. However, it generates substantial cash, with trailing twelve-month free cash flow of $2.38 billion, providing ample coverage for its dividend, which has a payout ratio of 82.14%. The current ratio of 0.75 suggests potential liquidity constraints in covering short-term obligations, but a return on equity of 134.55% (though this figure appears anomalously high and may be a data artifact) and a return on assets of 10.16% indicate efficient use of capital. The strong free cash flow generation supports the company's ability to fund its dividend and strategic initiatives like the Kenvue acquisition internally.
Quarterly Revenue
$4.1B
2025-12
Revenue YoY Growth
-0.17%
YoY Comparison
Gross Margin
+0.35%
Latest Quarter
Free Cash Flow
$2.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KMB Overvalued?
Given that Kimberly-Clark has positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 16.63x and a forward PE of 12.88x. The gap between the trailing and forward multiples implies the market expects a meaningful recovery in earnings, with analysts projecting forward EPS of $9.14, a significant increase from the most recent quarterly EPS of $1.50. Compared to typical industry averages for stable consumer staples, a trailing PE in the mid-teens is generally reasonable, though the forward multiple suggests a discount if growth materializes. A direct industry average comparison is not provided in the data, but the current multiples sit below the stock's own historical peaks. The stock's valuation is near the bottom of its own historical range. For instance, historical PE ratios over recent quarters have ranged from as low as 13.17x (Q3 2024) to over 114x (Q2 2023, an outlier period), with more recent readings in the 16-24x range before the price decline. The current trailing PE of 16.63x is towards the lower end of this recent band, suggesting the market is pricing in pessimistic expectations, potentially creating a value opportunity if the company's fundamentals stabilize or the Kenvue acquisition proves accretive.
PE
16.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 13x~114x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are elevated. The company's debt-to-equity ratio of 4.77 indicates a highly leveraged balance sheet, which increases interest expense vulnerability and could complicate funding for the Kenvue acquisition. Revenue is contracting sharply, with a 17.2% YoY decline in Q4 2025, raising questions about pricing power and volume trends in its core categories. While free cash flow of $2.38 billion is strong, the high dividend payout ratio of 82% leaves limited room for error, and the low current ratio of 0.75 points to potential short-term liquidity constraints.
Market & Competitive Risks center on valuation and execution. Despite the 32% price decline, the stock's forward P/E of 12.9x is only a discount if the projected EPS recovery to $9.14 materializes; failure to meet these estimates could lead to further multiple compression. The stock's catastrophic -60.4% relative underperformance versus the S&P 500 over the past year suggests a severe loss of investor confidence that may not be easily regained, creating a sentiment overhang. The pending Kenvue acquisition, while a potential catalyst, introduces significant integration and execution risk, as highlighted by recent news framing similar sector deals as 'risky'.
Worst-Case Scenario involves a continuation of the current downtrend exacerbated by a failed strategic pivot. A sequence where Q2 2026 revenue misses estimates, the Kenvue deal faces regulatory delays or financing issues, and rising interest rates pressure the highly leveraged balance sheet could trigger a crisis of confidence. This could lead analysts to slash EPS estimates toward the low end of $8.98 and the stock to re-test and break its 52-week low of $92.42. A realistic downside from the current $97.60 could be a further 20-25% decline, pushing the stock toward the $75-$80 range, representing a max drawdown exceeding the recent -35.3%.
FAQ
The key risks, in order of severity, are: 1) Financial Risk: An extremely high debt-to-equity ratio of 4.77 limits flexibility and increases vulnerability to rising rates. 2) Operational Risk: A severe and persistent revenue contraction, with Q4 2025 sales down 17.2% YoY, threatens the core business model. 3) Sentiment Risk: Catastrophic -60.4% relative underperformance versus the market indicates a broken narrative that may not recover quickly. 4) Acquisition Risk: The planned Kenvue deal introduces integration, financing, and execution uncertainty over the next 18 months.
The 12-month forecast for KMB is a range-bound outcome with a skew to the downside. The base case (60% probability) sees the stock trading between $100 and $110, supported by its dividend but capped by weak growth. The bull case (25%) envisions a rally to $115-$125 on successful stabilization and acquisition progress. The bear case (15%) projects a drop to $85-$92 if operational deterioration continues. The most likely scenario is the base case, which assumes the company meets analyst EPS estimates near $9.14 but fails to re-ignite revenue growth, resulting in sideways price action.
KMB appears fairly valued to slightly undervalued based on forward earnings, but the valuation is not a clear bargain. The forward P/E of 12.9x is a discount to its trailing P/E of 16.6x and suggests the market expects meaningful EPS growth to $9.14. However, this multiple is only cheap if the company halts its revenue decline. Compared to its own historical range and given its defensive sector, the current multiple reflects significant pessimism. The market is valuing KMB as a company with stalled growth and high financial risk, which aligns with the current fundamental data, implying it is fairly valued, not deeply undervalued.
KMB is a conditional buy only for specific investor profiles. For income-seeking investors with a long-term horizon and high risk tolerance regarding business turnaround, the 4.94% yield supported by $2.38B in annual free cash flow offers compelling compensation. However, for growth-oriented investors, it is not a good buy due to the severe -17.2% revenue decline and high debt load of 4.77x. The stock could be a good buy on further weakness below $95 for yield-focused portfolios, but investors must be prepared for potential capital stagnation and high volatility around earnings.
KMB is strictly a long-term investment, with a suggested minimum holding period of 3-5 years. Its low beta of 0.31 makes it unsuitable for short-term trading due to likely low volatility and lack of near-term catalysts. The investment thesis is predicated on collecting the high dividend while awaiting a multi-year turnaround and the integration of the Kenvue acquisition in late 2026. Short-term traders would find better opportunities elsewhere, as KMB's path to recovery is measured in quarters, not weeks. Only investors willing to lock in the yield and wait for fundamental improvement should consider a position.